Inc. (NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway, today announced the closing of its ...
Inc. (NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway, today announced the pricing of a firm ...
Solaris energy Infrastructure (NYSE: SEI) recently announced the pricing of its underwritten public offering of 6,500,000 shares of its Class A common stock, par value $0.01 per share, at a public ...